Covid-19 roundup: Researchers urge Pfizer to adopt high safety standard, hold vaccine EUA until late November
Pfizer has been the only player in the global Covid-19 vaccine race that’s predicted that it will know whether its candidate, discovered by BioNTech, meets the regulatory standards for emergency use authorization by October. But more than 60 leading researchers and bioethicists are urging them to wait.
In a letter first reported by Bloomberg Law, the prominent group of scientists argued that under a rigorous safety standard, all 30,000 trial participants should be monitored for a minimum of two months after receiving the second dose of the vaccine. Since many in the Pfizer trial have not yet received that second dose, investigators should keep monitoring them until at least late November before the company files for an EUA, they argued.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.